GSK Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Oct 6, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Oct 6, 2025 |
| Risk Level | low |
| Pages | 10 |
| Reading Time | 12 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, transaction-in-own-shares
TL;DR
GSK is buying back its own stock via BNP Paribas.
AI Summary
GSK plc announced on October 6, 2025, that it purchased a certain number of its own ordinary shares of 31 1/4 pence each, acting through its broker, BNP Paribas SA. The filing does not specify the exact number of shares or the total dollar amount involved in these transactions.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This is a routine disclosure of share repurchases, which is common for publicly traded companies.
Key Players & Entities
- GSK plc (company) — Registrant
- BNP Paribas SA (company) — Broker executing share purchases
- October 2025 (date) — Reporting period for transactions
- 31 1/4 pence (dollar_amount) — Nominal value of ordinary shares
FAQ
What is the total number of GSK ordinary shares purchased by the company?
The filing states that GSK purchased 'the following number of the Company's ordinary shares' but does not specify the exact quantity.
What was the total cost of the share repurchases?
The filing does not disclose the total dollar amount spent on the purchased shares.
On what date were these share transactions reported?
The report is for the month of October 2025 and was filed as of October 6, 2025.
Which broker acted on behalf of GSK for these share purchases?
BNP Paribas SA acted as the broker for GSK in these transactions.
What is the nominal value of GSK's ordinary shares mentioned in the filing?
The nominal value of GSK's ordinary shares is stated as 31 1/4 pence.
Filing Stats: 3,067 words · 12 min read · ~10 pages · Grade level 2.8 · Accepted 2025-10-06 07:08:41
Filing Documents
- a0832c.htm (6-K) — 4188KB
- 0001654954-25-011459.txt ( ) — 4189KB
From the Filing
IN OWN SHARES a0832c   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of October 2025   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .       Transaction in own shares   GSK plc (the " Company ") announces today   acting through BNP Paribas SA (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.   Date of purchase:   03 October 2025   Aggregate number of ordinary shares of  31¼  pence each purchased:   350,000   Lowest price paid per share (GBp):   1,598.00p   Highest price paid per share (GBp):   1,649.00p   Volume-weighted average price paid per share (GBp):   1,631.45p   The purchased shares will be held   as Treasury shares.                                                                                                                            Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker, as announced on 30 September 2025.  Since 30 September 2025 the Company has purchased 1,252,000 ordinary shares.   Following the above purchase, the Company will hold 248,716,844 ordinary shares in treasury and have 4,066,691,695 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is   4,066,691,695. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is 6.12 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.   Schedule of Purchases   Shares purchased:     GSK plc (ISIN: GB00BN7SWP63)   Date of purchases:      03 October 2025   Investment firm:         BNP Paribas SA   Aggregated information per trading venue:   Venue   Number of ordinary shares purchased   Highest price paid (per ordinary share)(GBp)   Lowest price paid (per ordinary share)(GBp)   Volume weighted average price paid (per ordinary share) (GBp)   BATE   38,710   1,649.00p   1,600.00p   1,630.74p   CHIX   142,141   1,649.00p   1,598.00p   1,631.82p   XLON   169,149   1,649.00p   1,600.50p   1,631.30p     Individual transactions:   Number of Shares   Price per Share (GBp)   Trading venue   Date of transaction   Time of transaction   Transaction reference number   250   1636.5   XLON   03-Oct-2025   08:01:03   20251003145960652   186   1636.5   XLON   03-Oct-2025   08:01:03   20251003145960654   88   1636.5   XLON   03-Oct-2025   08:01:03   20251003145960656